Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A prospective, controlled, randomized, multicenter study whose goal is to compare the
efficacy of an autophagy inhibitor (GNS561), an anti-NKG2A (monalizumab) and an anti-C5aR
(avdoralimab) versus standard of care in patients with advanced or metastatic cancer who have
Sars-CoV-2 infection not eligible to a resuscitation unit.
According to their severity level at the time of enrolment, eligible patients will be
randomized into 2 different cohorts:
- COHORT 1 (mild symptoms or asymptomatic): GNS561 vs anti-NKG2A vs standard of care
(randomization ratio 1:1:1).
- COHORT 2 (moderate/severe symptoms): anti-C5aR vs standard of care (randomization ratio
1:1).